Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02616393
Title Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kadmon Corporation, LLC
Indications

lung non-small cell carcinoma

Therapies

Tesevatinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.